Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid

OncoImmunology

Volumn 6, Issue 6, 2017, Pages

  Lennicke, Claudia ^a   Rahn, Jette ^a   Bukur, Jürgen ^a   Hochgräfe, Falko ^b   Wessjohann, Ludger A ^c   Lichtenfels, Rudolf ^a   Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c LEIBNIZ INSTITUTE OF PLANT BIOCHEMISTRY   (Germany)

Author keywords

2D DIGE; anti tumoral immune response; APM components; methylseleninic acid; MHC class I; selenium

Indexed keywords

CALRETICULIN; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GALECTIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEROXIREDOXIN 1; PROGRAMMED DEATH 1 LIGAND 2; PROTEIN DISULFIDE ISOMERASE; PROTEIN KINASE B; SELENOMETHIONINE;

APOPTOSIS; ARTICLE; CELL MIGRATION ASSAY; CELL SURVIVAL; CELL VIABILITY; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; FLOW CYTOMETRY; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; HUMAN CELL; INNATE IMMUNITY; MELANOMA; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; XTT ASSAY;

EID: 85019545104     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1259049     Document Type: Article

References (70)

1. Lunøe K, Gabel-Jensen C, Stürup S, Andresen L, Skov S, Gammelgaard B. Investigation of the selenium metabolism in cancer cell lines. Metallomics 2011; 3:162-8; PMID:21161099; https://doi.org/10.1039/C0MT00091D
2. Yan L, DeMars LC. Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice. Int J Cancer 2012; 131:1260-6; PMID:22095442; https://doi.org/10.1002/ijc.27355
3. Chen YC, Prabhu KS, Mastro AM. Is selenium a potential treatment for cancer metastasis? Nutrients 2013; 5:1149-68; PMID:23567478; https://doi.org/10.3390/nu5041149
4. Chen YC, Prabhu KS, Das A, Mastro AM. Dietary selenium supplementation modifies breast tumor growth and metastasis. Int J cancer 2013; 133:2054-64; PMID:23613334; https://doi.org/10.1002/ijc.28224
5. Labunskyy VM, Hatfield DL, Gladyshev VN. Selenoproteins:molecular pathways and physiological roles. Physiol Rev 2014; 94:739-77; PMID:24987004; https://doi.org/10.1152/physrev.00039.2013
6. El-Bayoumy K, Sinha R. Molecular chemoprevention by selenium:a genomic approach. Mutat Res 2005; 591:224-36; PMID:16099479; https://doi.org/10.1016/j.mrfmmm.2005.04.021
7. Schrauzer GN, White DA, Schneider CJ. Cancer mortality correlation studies–III:statistical associations with dietary selenium intakes. Bioinorg Chem 1977; 7:23-31; PMID:856291; https://doi.org/10.1016/S0006-3061(00)80126-X
8. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276:1957-63; PMID:8971064; https://doi.org/10.1001/jama.1996.03540240035027
9. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998; 128:1845-54; PMID:9808633
10. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers:the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39-51; PMID:19066370; https://doi.org/10.1001/jama.2008.864
11. Whanger PD. Selenium and its relationship to cancer:an update. Br J Nutr 2004; 91:11-28; PMID:14748935; https://doi.org/10.1079/BJN20031015
12. Rayman MP. Selenium in cancer prevention:a review of the evidence and mechanism of action. Proc Nutr Soc 2005; 64:527-42; PMID:16313696; https://doi.org/10.1079/PNS2005467
13. Ip C, Ganther HE. Activity of methylated forms of selenium in cancer prevention. Cancer Res 1990; 50:1206-11; PMID:2105164
14. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid:evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000; 60:2882-6; PMID:10850432
15. Fernandes AP, Wallenberg M, Gandin V, Misra S, Tisato F, Marzano C, Rigobello MP, Kumar S, Björnstedt M. Methylselenol formed by spontaneous methylation of selenide is a superior selenium substrate to the thioredoxin and glutaredoxin systems. PLoS One 2012; 7:e50727; PMID:23226364; https://doi.org/10.1371/journal.pone.0050727
16. Zeng H, Wu M. The Inhibitory Efficacy of Methylseleninic Acid Against Colon Cancer Xenografts in C57BL/6 Mice. Nutr Cancer 2015; 67:831-8; PMID:26011019; https://doi.org/10.1080/01635581.2015.1042547
17. Cassidy PB, Fain HD, Cassidy JP, Tran SM, Moos PJ, Boucher KM, Gerads R, Florell SR, Grossman D, Leachman SA. Selenium for the prevention of cutaneous melanoma. Nutrients 2013; 5:725-49; PMID:23470450; https://doi.org/10.3390/nu5030725
18. Qi Y, Fu X, Xiong Z, Zhang H, Hill SM, Rowan BG, Dong Y. Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One 2012; 7:e31539; PMID:22348099; https://doi.org/10.1371/journal.pone.0031539
19. Hu C, Liu M, Zhang W, Xu Q, Ma K, Chen L, Wang Z, He S, Zhu H, Xu N. Upregulation of KLF4 by methylseleninic acid in human esophageal squamous cell carcinoma cells:Modification of histone H3 acetylation through HAT/HDAC interplay. Mol Carcinog 2015; 54:1051-9; PMID:24789055; https://doi.org/10.1002/mc.22174
20. Kassam S, Goenaga-Infante H, Maharaj L, Hiley CT, Juliger S, Joel SP. Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines. Cancer Chemother Pharmacol 2011; 68:815-21; PMID:21519842; https://doi.org/10.1007/s00280-011-1649-1
21. Doyle K, Fitzpatrick FA. Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J Biol Chem 2010; 285:17417-24; PMID:20385560; https://doi.org/10.1074/jbc.M109.089250
22. Zhang J, Basher F, Wu JD. NKG2D Ligands in Tumor Immunity:Two Sides of a Coin. Front Immunol 2015; 6:97; PMID:25788898; https://doi.org/10.3389/fimmu.2015.00097
23. Hagemann-Jensen M, Uhlenbrock F, Kehlet S, Andresen L, Gabel-Jensen C, Ellgaard L, Gammelgaard B, Skov S. The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D. J Biol Chem 2014; 289:31576-90; PMID:25258323; https://doi.org/10.1074/jbc.M114.591537
24. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-9; PMID:10426993; https://doi.org/10.1126/science.285.5428.727
25. Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006; 7:755-62; PMID:16732291; https://doi.org/10.1038/ni1350
26. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002; 17:19-29; PMID:12150888; https://doi.org/10.1016/S1074-7613(02)00333-3
27. Guo ZY, Lv YG, Wang L, Shi SJ, Yang F, Zheng GX, Wen WH, Yang AG., Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. Cell Immunol 2015; 293:10-6; PMID:25461612; https://doi.org/10.1016/j.cellimm.2014.10.003
28. Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV. Non-classical HLA-class I expression in serous ovarian carcinoma:Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. Oncoimmunology 5:e1052213; PMID:26942060; https://doi.org/10.1080/2162402X.2015.1052213
29. Tremante E, Ginebri A, Lo Monaco E, Benassi B, Frascione P, Grammatico P, Cappellacci S, Catricalà, C, Arcelli D, Natali PG, et al. A melanoma immune response signature including Human Leukocyte Antigen-E. Pigment Cell Melanoma Res 2014; 27:103-12; PMID:24011128; https://doi.org/10.1111/pcmr.12164
30. Pietra G, Romagnani C, Manzini C, Moretta L, Mingari MC. The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol 2010; 2010:907092; PMID:20634877; https://doi.org/10.1155/2010/907092
31. Enqvist M, Nilsonne G, Hammarfjord O, Wallin RP, Björkström NK, Björnstedt M, Hjerpe A, Ljunggren HG, Dobra K, Malmberg KJ, et al. Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells. J Immunol 2011; 187:3546-54; PMID:21890659; https://doi.org/10.4049/jimmunol.1100610
32. Seliger B. The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors. J Immunotoxicol 2014; 11:308-10; PMID:24479372; https://doi.org/10.3109/1547691X.2013.875084
33. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 2016; 39:44-51; PMID:26796069; https://doi.org/10.1016/j.coi.2015.12.007
34. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3:999-1005; PMID:12407407; https://doi.org/10.1038/ni1102-999
35. Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules:implications for tumor immune escape. Cancer Immunol Immunother 2004; 53:904-10; PMID:15069585; https://doi.org/10.1007/s00262-004-0517-9
36. García-Lora A, Algarra I, Collado A, Garrido F. Tumour immunology, vaccination and escape strategies. Eur J Immunogenet 2003; 30:177-83; PMID:12786993; https://doi.org/10.1046/j.1365-2370.2003.00384.x
37. Oliveira CC, van Hall T. Alternative antigen processing for MHC class I:Multiple roads lead to Rome. Front Immunol 2015; 6:298; PMID:26097483; https://doi.org/10.3389/fimmu.2015.00298
38. Garrido F, Romero I, Aptsiauri N, Garcia-Lora AM. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int J cancer 2016; 138:271-80; PMID:25471439; https://doi.org/10.1002/ijc.29375
39. Makhadiyeva D, Lam L, Moatari M, Vallance J, Zheng Y, Campbell EC, Powis SJ. MHC class I dimer formation by alteration of the cellular redox environment and induction of apoptosis. Immunology 2012; 135:133-9; PMID:22044191; https://doi.org/10.1111/j.1365-2567.2011.03518.x
40. Kukita K, Tamura Y, Tanaka T, Kajiwara T, Kutomi G, Saito K, Okuya K, Takaya A, Kanaseki T, Tsukahara T, et al. Cancer-associated oxidase ERO1-α regulates the expression of MHC class I molecule via oxidative folding. J Immunol 2015; 194:4988-96; PMID:25870246; https://doi.org/10.4049/jimmunol.1303228
41. Toker A, Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul 2014; 55:28-38; PMID:24794538; https://doi.org/10.1016/j.jbior.2014.04.001
42. Lennicke C, Rahn J, Lichtenfels R, Wessjohann LA, Seliger B. Hydrogen peroxide - Production, fate and role in redox signaling of tumor cells. Cell Commun Signal 2015; 13; PMID:26369938; https://doi.org/10.1186/s12964-015-0118-6
43. Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, Santopaolo M, et al. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. Cell Death Dis 2016; 7:e2120; PMID:26913609; https://doi.org/10.1038/cddis.2016.28
44. Kang K, Park B, Oh C, Cho K, Ahn K. A role for protein disulfide isomerase in the early folding and assembly of MHC class I molecules. Antioxid Redox Signal 2009; 11:2553-61; PMID:19388826; https://doi.org/10.1089/ars.2009.2465
45. Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol 2003; 23:8786-94; PMID:14612418; https://doi.org/10.1128/MCB.23.23.8786-8794.2003
46. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001; 61:1095-9; PMID:11221838
47. Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A 2016; 113:5999-6004; PMID:27162338; https://doi.org/10.1073/pnas.1602069113
48. Misra S, Boylan M, Selvam A, Spallholz JE, Björnstedt M. Redox-active selenium compounds - from toxicity and cell death to cancer treatment. Nutrients 2015; 7:3536-56; PMID:25984742; https://doi.org/10.3390/nu7053536
49. Jucaud V, Ravindranath MH, Terasaki PI. Immunobiology of HLA Class-Ib Molecules in Transplantation. SOJ Immunol 2015; 3:1-15; https://doi.org/10.15226/2372-0948/3/4/00137
50. Pietra G, Romagnani C, Moretta L, Mingari MC. HLA-E and HLA-E-bound peptides:recognition by subsets of NK and T cells. Curr Pharm Des 2009; 15:3336-44; PMID:19860683; https://doi.org/10.2174/138161209789105207
51. Sensi M, Pietra G, Molla A, Nicolini G, Vegetti C, Bersani I, Millo E, Weiss E, Moretta L, Mingari MC, et al. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. Int Immunol 2009; 21:257-68; PMID:19181932; https://doi.org/10.1093/intimm/dxn141
52. Seliger B, Jasinski-Bergner S, Quandt D, Stoehr C, Bukur J, Wach S, Legal W, Taubert H, Wullich B, Hartmann A. HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget 2016; 7:7-22; PMID:27589686; https://doi.org/10.18632/oncotarget.11744
53. Tsvetkov P, Reuven N, Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ 2010; 17:103-8; PMID:19557012; https://doi.org/10.1038/cdd.2009.67
54. Zhu K, Wang J, Zhu J, Jiang J, Shou J, Chen X. p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene 1999; 18:7740-7; PMID:10618714; https://doi.org/10.1038/sj.onc.1203235
55. Wang L, Guo X, Wang J, Jiang C, Bosland MC, Lü, J, Deng Y. Methylseleninic acid superactivates p53-senescence cancer progression barrier in prostate lesions of pten-knockout mouse. Cancer Prev Res (Phila) 2016; 9:35-42; PMID:26511486; https://doi.org/10.1158/1940-6207.CAPR-15-0236
56. Zhang Y, Zheng S, Zheng JS, Wong KH, Huang Z, Ngai SM, Zheng W, Wong YS, Chen T. Synergistic induction of apoptosis by methylseleninic acid and cisplatin, the role of ROS-ERK/AKT-p53 pathway. Mol Pharm 2014; 11:1282-93; PMID:24555485; https://doi.org/10.1021/mp400749f
57. Hubackova S, Kucerova A, Michlits G, Kyjacova L, Reinis M, Korolov O, Bartek J, Hodny Z. IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2. Oncogene 2016; 35:1236-49; PMID:25982278; https://doi.org/10.1038/onc.2015.162
58. Manea A, Tanase LI, Raicu M, Simionescu M. Jak/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2010; 30:105-12; PMID:19834108; https://doi.org/10.1161/ATVBAHA.109.193896
59. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schröter F, Prozorovski T, Lange N, Steffen J, Rieger M, et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010; 142:613-24; PMID:20723761; https://doi.org/10.1016/j.cell.2010.07.036
60. Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect:Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol 2015; 9:1447-57; PMID:25957812; https://doi.org/10.1016/j.molonc.2015.04.002
61. Steven A, Heiduk M, Recktenwald CV, Hiebl B, Wickenhauser C, Massa C, Seliger B. Colorectal Carcinogenesis:Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo. Mol Cancer Res 2015; 13:1248-62; PMID:25934695; https://doi.org/10.1158/1541-7786.MCR-14-0590
62. Lennicke C, Rahn J, Kipp AP, Dojčinović BP, Müller A, Wessjohann LA, Lichtenfels R, Seliger B. Individual effects of different selenocompounds on the hepatic proteome and energy metabolism. BBA - Gen Subj 2016; 30304-X; PMID:27565357; https://doi.org/10.1016/j.bbagen.2016.08.015
63. Mi H, Poudel S, Muruganujan A, Casagrande JT, Thomas PD. PANTHER version 10:expanded protein families and functions, and analysis tools. Nucleic Acids Res 2016; 44:D336-42; PMID:26578592; https://doi.org/10.1093/nar/gkv1194
64. Jasinski-Bergner S, Stehle F, Gonschorek E, Kalich J, Schulz K, Huettelmaier S, Braun J, Seliger B. Identification of 14-3-3β gene as a novel miR-152 target using a proteome-based approach. J Biol Chem 2014; 289:31121-35; PMID:25228695; https://doi.org/10.1074/jbc.M114.556290
65. Tipple TE, Rogers LK. Methods for the determination of plasma or tissue glutathione levels. Methods Mol Biol 2012; 889:1-8; PMID:22669655; https://doi.org/10.1007/978-1-61779-867-2_1
66. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. Primer3-new capabilities and interfaces. Nucleic Acids Res 2012; 40:e115; PMID:22730293; https://doi.org/10.1093/nar/gks596
67. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45; PMID:11328886; https://doi.org/10.1093/nar/29.9.e45
68. Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B. Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem 2010; 285:30419-26; PMID:20663889; https://doi.org/10.1074/jbc.M109.094284
69. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54; PMID:942051; https://doi.org/10.1016/0003-2697(76)90527-3
70. Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Müller A, Hiebl B, Holzhausen HJ, et al. HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Mol Cancer Res 2013; 11:1462-77; PMID:24025972; https://doi.org/10.1158/1541-7786.MCR-13-0125